ClinicalTrials.gg

Nasopharyngeal Carcinoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 683 studies for Nasopharyngeal Carcinoma across more than 10 countries. 270 are recruiting or about to start. 612 of them are mainly about Nasopharyngeal Carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 1,138 studies for Nasopharyngeal Carcinoma. How that becomes 681 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Nasopharyngeal Carcinoma, and those it files under no condition that list Nasopharyngeal Carcinomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,138Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4List Nasopharyngeal Carcinoma as a condition, but the registry did not file them under itMost often written as “Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia,” (1), “Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis” (1), and “Otitis Media With Effusion After Nasopharyngeal Carcinoma” (1). The registry filed them under other conditions only, most often Nasopharyngeal Neoplasms (2) and Deglutition Disorders (1).
  3. −453Match it another way128 name it in the title and 325 by a synonym or other text the search reads.
  4. 681The count on this page32 of them list Nasopharyngeal Carcinoma in their own words; the registry filed them under no condition.

Status

Recruiting
186
Status unknown
172
Completed
136
Not yet recruiting
83
Active, not recruiting
66
Terminated
28

Phase

Phase 2
294
Phase 3
149
Phase 1
80
Early Phase 1
7
Phase 4
4

Where

China
489
United States
59
Singapore
34
Taiwan
31
Hong Kong
19
Canada
11

Who develops what

Add Nasopharyngeal Carcinoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 6 companies, 7 with this as their studies’ main aim; 5 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Sichuan Biokin Pharmaceutical, CSPC Pharmaceutical Group and Fosun Pharma here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CisplatinRecent, repeated
Evidence
  • NCT07797881 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “Cisplatin” · registered Aug 2026
  • NCT07783321 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “cisplatin” · registered Aug 2026
  • NCT07258979 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Nov 2025
  • NCT05576272 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Cisplatin” · registered Sep 2022
  • NCT05294172 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · background · “Cisplatin” · registered Mar 2022
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed45 studies
GemcitabineRecent, repeated
Evidence
  • NCT07797881 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “Gemcitabine” · registered Aug 2026
  • NCT07783321 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “gemcitabine” · registered Aug 2026
  • NCT06629597 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Sep 2024
  • NCT05576272 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Gemcitabine” · registered Sep 2022
  • NCT05294172 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · background · “Gemcitabine” · registered Mar 2022
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed45 studies
CapecitabineRecent, repeated
Evidence
  • NCT06629597 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered Sep 2024
  • NCT05717764 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Capecitabine” · registered Jan 2023
  • NCT05126719 · Lepu Biopharma Co., Ltd. · Phase 2 · live · comparator · “Capecitabine tablets” · registered Nov 2021
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized22 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
izalontamab brengitecan☆ Track2 live phase-3 studies: NCT07783321, NCT06118333Sichuan Biokin Pharmaceutical Co., Ltd.
tambotatug pelitecan☆ Track1 live phase-3 study: NCT06629597MediLink Therapeutics (Suzhou) Co., Ltd.
becotatug vedotin☆ Track1 live phase-3 study: NCT06976190Lepu Biopharma Co., Ltd.
pucotenlimab☆ Track1 live phase-3 study: NCT06976190Lepu Biopharma Co., Ltd.
Anti-EGFR Antibody-drug Conjugate CPO301☆ Track1 live phase-3 study: NCT07925021CSPC Pharmaceutical Group Limited

The 5 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 main aimNCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) — primary endpoint: Objective Response Rate (ORR) · 386 enrolled
  • 22 Nov 2026 est.Anti-PD-L1 Antibody-drug Conjugate HLX43 · Fosun Pharma · Phase 2 main aimNCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy — primary endpoint: ORR · 70 enrolled
  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 named, not the main aimNCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors — primary endpoint: Objective response rate (ORR) · 121 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Nasopharyngeal Carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 68 open · Antimetabolites 19 open · Tyrosine kinase inhibitors (TKIs) 6 open · Angiogenesis inhibitors 5 open · Antimitotic agents 4 open

Coming up

64studies finish main data collection within a year19 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger. 9 (5%) take children under 18. 0 (0%) are for women only and 2 (1%) for men only; 8 (4%) take healthy volunteers.

Recruiting studies that take each age, of 186
AgeWomenMen
109 (5%)9 (5%)
18175 (94%)176 (95%)
30180 (97%)182 (98%)
40181 (97%)183 (98%)
50181 (97%)183 (98%)
65177 (95%)178 (96%)
7583 (45%)84 (45%)
8546 (25%)47 (25%)

Across all 683 studies, recruiting or not: 68% stop at 75 or younger and 22% at 65; 9% take children; <1% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Nasopharyngeal Carcinoma studies take

Of 143 phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo37–75 · 28 studies——
Phase 243 mo28–65 · 143 studies—49 mo31–74 · 128 studies
Phase 369 mo51–82 · 84 studies——
Interventional, no phase45 mo22–… · 49 studies——
Observational55 mo36–155 · 52 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 683. Browse all 683 → or search them.